Management and Advisory Board

Dr. Holman is the founding rheumatologist at Pacific Rheumatology Associates Inc PS, Director of Research at Pacific Rheumatology Research Inc., a former President of the Northwest Rheumatism Society (2005) and a Clinical Associate Professor of Medicine at the University of Washington.   He has 25 year clinical and 19 year rheumatology research career experience with 16 lead author published papers, 25 lead author published abstracts.   For Inmedix, he has designed, completed and published 15 clinical studies, including FDA negotiations, involving nearly 1500 patients.

With Tim Sciarrillo, Dr. Holman founded Inmedix, and after 3 prospective, clinical trials, eventually sold an international patent portfolio to Boehringer-Ingelheim for $10,000,000 in 2007.  In 2015, Dr. Holman converted Inmedix LLC into Inmedix Inc to bring next-generation heart rate variability (HRV) to clinicians on a reimbursed, scalable and actionable cloud platform.

Dr. Holman's research highlights include reporting and eventually licensing use of dopamine agonists as a treatment of fibromyalgia, exploring the impact of hypermobility syndromes, evaluating established and innovative autonomic nervous system (ANS) analysis with 5-min heart rate variability (HRV) in patients with rheumatoid arthritis and other autoimmune diseases, and broadening understanding of pain in patients with PC3 (positional cervical cord compression) using dynamic flexion-extension, cervical magnetic resonance imaging (dMRI). 

www.linkedin.com/in/AndrewJHolman

Mr. Sciarrillo has been a C-level Executive for 25+ years in mid and small entrepreneurial companies in the manufacturing, management consulting and real estate industries. He was lead negotiator for Inmedix's historic sale of its method-of-use patents for treatment of fibromyalgia with dopamine agonists in 2007. He is also CEO of The New England Group, a management consulting firm founded by him in 1989. Tim’s professional experience also includes many years at the accounting firm Deloitte, Haskins & Sells as both an employee and a consultant to the C-level executives. He graduated from the College of the Holy Cross with a degree in Physics.

Prior to joining Inmedix, Steven was part of the executive management team of Light Sciences Oncology, a private venture-backed biotechnology company that raised over $250 Million to develop a combinational product (drug and device) for the treatment of cancer and other indications.  Over his 17 years at Light Sciences Oncology Steven held positions with escalating responsibility from design engineering, product development, non-clinical research, business development and licensing, market research, and corporate strategy and development.  He was intimately involved in the growth of Light Sciences from the startup phase through late stage clinical testing and eventual out-licensing of the technology.  Light Sciences investigated and researched its proprietary platform technology in 7 Phase 1 Studies, 5 Phase 2 Studies, and 2 Phase 3 Studies within 3 separate IND’s.  Steven holds a B.S. in Materials Science Engineering (Ceramic Engineering), M.S. in Bioengineering (Medical Engineering), and an M.B.A. from the University of Washington.

Glynis Thakur is a healthcare CEO and consultant with over 25 years’ experience.  She comes to Inmedix, Inc. to take charge of finance and reimbursement development and operations.

 In her years as a C-level executive and consultant, Glynis has advised on, implemented, and led:  Conflict Resolution, Contract Negotiations, Corporate Buy-in Negotiations, Start-ups, mergers and acquisitions, Strategic Planning and Operations, Organizational Restructuring, Strategic Alliances, Finance, including Forensic Audits and Medical Practice Valuations, Litigation Consulting including Contract Negotiations and Medicolegal Disputes, Mediation and Arbitration, Crisis Services during Federal Investigations (fraud and antitrust), Fact finding and clarification of unique situations.

Glynis also enjoys writing, teaching and giving talks to attorneys and physicians, as well as residents and fellows at the UW Medical Center. 

www.linkedin.com/in/glynis-thakur-55a54811

Daniel heads commercialization, academic and research coordination efforts in the United Kingdom and Europe through our subsidiary, Inmedix UK, Ltd.  He joins Inmedix after a long research association with Dr. Holman in the field of fibromyalgia.  He has an elite sports background as well as pharmaceutical commercialization expertise at Baxter Healthcare as a sales representative and accounts/contract manager and as a regional development executive at BUPA (now Spire) Health Services.  Daniel has intimate familiarity with rheumatology clinical practice.  For nearly twenty years, he was clinic manager for the UK FM/ME Clinics working with Professor John E. Davies, MD, as well as providing private practice marketing/business consultancy and management at the Fibromyalgia Clinic, Harley Street, London. BS, Florida State University.

Jolene Anderson is a seasoned business executive working with a global client list seeking to invest in commercial real estate and providing business facilitation for emerging companies, both public and private. Ms. Anderson has facilitated the sales and financing of hotels, resorts, and multifamily properties in WA, OR, ID, CA, FL, and HI since 1989. Her extensive network of business executives and mentors includes key players in industry and commerce. She has advised companies as a business strategist and facilitated expansion into US markets, including advising product companies who desired to expand their product line into the US and Canada and was a principal in a global spa/health education company and corporate travel company. Recent assignments include consulting for a public company, located in Boise, ID, focusing on science, technology, engineering and math for K-12 students (STEM) education, where she served as the Director of Investor and Community Relations. She has also advised companies in the Seattle biotech community and serves on the boards of non profits focusing on healthy communities and education. Ms. Anderson served as a volunteer at the Chris Elliott Fund for Brain Cancer Research, Washington Women for Employment and Education, Table Captain for the Annual YWCA Fundraiser, volunteer for Children’s Orthopedic Hospital and is past President of the Kiwanis Club of Seattle, and Soroptimist International Seattle Metro. She has produced a radio show on healthy families and was the editor of an online magazine. She is a problem solver committed to providing consulting for companies through introducing strategic partnerships and mentorship.

StarFish Medical is an integral partner to Inmedix for successful completion of every level of its product development, US regulatory, quality management systems, and commercial manufacturing. During this working relationship for 5+ years as many as 16 engineers and other specialists at Starfish have worked side by side Inmedix to bring CloudHRV to US clinicians.

Starfish is Canada’s leading Medical Device Design service provider with a full complement of design, development, and manufacturing services in Victoria and Toronto. They successfully partner with innovative companies (both large and small) to create breakthrough products for a number of medical specialty areas. Medical device product definition, technical engineering and product development use its proprietary Pathfinder™ process.   Prototype and volume production are delivered in an ISO 13485 certified facility with FDA registration and class 10,000 clean room capabilities.

Doug Cooper is a versatile financial professional who began his career in public accounting at Deloitte, then spent six years as the Planning & Analysis Project Manager for commercial lender MetLife Capital.  Following his early experience in auditing and commercial finance, Doug spent the next 20 years in investment banking at Zachary Scott & Company in Seattle, where he played a vital role in the execution of middle market M&A transactions with combined enterprise value of well over a billion dollars.  Doug is well-recognized for his combination of financial accounting expertise coupled with exceptional forecast modeling and programming skills.

Dennis most recently served as Vice President of Business Development and Emerging Products at Exagen Inc, a San Diego based, medical diagnostic company with a focus in autoimmune rheumatic diseases. During his nine years at Exagen, Dennis closed a number of collaboration partnerships with academic institutions, diagnostic and biopharmaceutical companies.  Most recently, he negotiated a successful, big pharma co-promotion deal for a biologic treatment for rheumatoid arthritis enabling Exagen’s IPO event. During his first five years at Exagen, Dennis also served as Vice President of Marketing launching a number of diagnostic products including the company’s flagship product AVISE CTD, a blood test for the differential diagnosis of lupus versus other autoimmune rheumatic diseases.

Prior to Exagen, Dennis served as Head of Strategic Business Development Gastroenterology at Prometheus Labs where he evaluated and closed a number of late-stage and marketed pharmaceutical assets for licensing and/or acquisition.

Dennis also served in senior marketing roles with a number of San Diego based emerging pharmaceutical companies, supporting their initial commercial build-up and launching their initial products.

Previous to San Diego, Dennis worked in a number of commercial positions with increasing responsibility at Eli Lilly and Company over a fifteen-year career involving pharmaceutical sales, market research, product marketing, hospital sales management, pricing/contracting, drug development and alliance management.

Dennis graduated with honors from Idaho State University with a Bachelor of Science degree in Pharmacy.

Alex is Founder & Principal of Allevo Advisors, providing technology, product, commercial, and organizational strategy consulting services to organizations focused on digital health, diagnostics, devices, and life science analytics.

Alex most recently served as Chief Information Officer at Vir Biotechnology, Inc, a San Francisco-based infectious disease therapeutics company. Alex joined in 2018 to set up Data Science and IT organizations for this fast-growing startup, building out a cloud-first data and IT infrastructure and multidisciplinary team to support lab research, clinical trials, contract manufacturing, quality, and administrative operations. Vir became a public company in 2019, and in 2020 discovered and co-developed the sorovimab antibody that was used globally in the fight against COVID-19.

Previously, Alex served as Chief Information Officer of Crescendo Bioscience, a startup focused on molecular diagnostics for autoimmune rheumatic diseases. At Crescendo, Alex led Informatics, IT, and Information Security, developing external web and mobile solutions for patients and physicians, and internal data and analytics solutions for scientific and commercial staff. He also provided leadership to other functions across the company including laboratory operations, customer service, and clinical trial design. Crescendo was acquired by Myriad Genetics in 2014.

Prior to Crescendo, Alex was Co-Founder and Chief Technology Officer at Entelos where he led the development of technology for virtual patient simulations and is an inventor on several related patents. He has held technical and management positions at Strategic Decisions Group, Oak Ridge National Laboratory, Honeybee Robotics, and the Institute for Defense Analyses. He received an AB in computer science and engineering sciences from Harvard College and an MS in computer science from the University of Tennessee.

Nathan Smith is an accomplished executive in healthcare finance, boasting a rich, two-decade-long history in the public market sector. Prior to his current role, Nathan served as the Chief Financial Officer at Blackrock Neurotech. There, he was instrumental in securing venture capital, formulating strategic plans, and crafting the company's organizational structure. His impactful stint at Myriad Genetics Inc. is a testament to his financial acumen, where he excelled in investor relations, spearheaded mergers, and acquisitions, and supervised the treasury, accounting, and financial planning & analysis departments. This substantial contribution played a vital role in the organization's expansion. Nathan holds a Master of Accountancy from the University of Virginia and earned his Bachelor of Science in Business Finance from Brigham Young University.

Brian brings over 30 years of experience to the team, working in the Medical Device, Biologics, and Pharmaceutical industries within Quality, Operations, and Engineering. Prior to this, Brian worked in the medical field as a Pathologist’s Assistant and Physician’s Assistant.

Brian holds numerous patents on several class III medical devices from permanently implantable devices and delivery systems to Oxygen generation systems and biopsy management and handling devices and systems.

Brian holds a Master of Science in Biomechanical Engineering and a PA with special study and practice in Diagnostic Medicine, and Surgical and Forensic Pathology from Stanford University Medical School. He also holds a Bachelor of Science in Systems Physiology and Chemistry from San Jose State University.

John R. and Eileen K. Reidman Professor of Medicine at Harvard Medical School and the R. Bruce and Joan M. Mickey Distinguished Chair in Rheumatology at the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital.  2000-01 President of the American College of Rheumatology.

William Bruce Professor and Vice Chair, Internal Medicine, Chief Division of Rheumatology, University of Nebraska Medical Center; 2012-13 President of the American College of Rheumatology

Professor of Medicine, University of Toronto; Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital

Biopharmaceutical consultant and Adjunct Clinical Professor of Medicine, Stanford University School of Medicine

Carl M Pearson Professor Emeritus, UCLA School of Medicine, University of Washington, University of Florence, Italy

Panel member Western Institutional Review Board, Puyallup, WA. Former head, Tacoma Center for Arthritis Research conducting 250 clinical research trials over 35-year research career

Head of Rheumatology and Translational Research at the Institute of Infection and Immunity and Director of the Cardiff Regional Experimental Arthritis Treatment and Evaluation (CREATE) Centre at Cardiff University School of Medicine

Professor of Musculoskeletal Sciences at the University of Oxford and Director of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences and chairs the NOCRI Translational Research Partnership

Professor of Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Vice Chairman of the Department of Rheumatic and Immunological Diseases, Co-director of the Center for Vasculitis Care and Research, and Director of the Cleveland Clinic's RJ Fasenmyer Center for Clinical Immunology at the Cleveland Clinic in Cleveland, Ohio.

President and Senior Associate of Arthritis & Rheumatism Disease Specialties (AARDS), Miami, FL. Board member on the American College of Rheumatology, past-President of the Florida Society of Rheumatology and a founder and past-President of the International Society of Musculoskeletal Imaging in Rheumatology.

Stuart Hwang is an Inmedix investor and corporate development professional with more than 20 years in drug and diagnostic development. He has had extensive experience in developing strategic partnerships and fundraising with a cumulative transaction value greater than $2B. Prior to Inmedix, he has had an active advisory practice as a consultant and in investment banking supporting emerging and established biotech companies develop and execute on corporate strategy and transactions including partnerships, licensing, fundraising and M&A. Earlier, he led business development at Astex (acquired by Otuska). Prior to that he held business development leadership roles at Perlegen and Agilent. He has led drug and diagnostic R&D teams at SuperGen, Cor Therapeutics, Millennium, Celera, Agilent and at UCSF/LBNL supporting 7 NME INDs and the development of 3 marketed drugs. He developed deep sequencing and genome partitioning algorithms (founding scientist, Celera Genomics) and several first whole genome arrays (Agilent) and partnered with pharma/biotech to integrate these novel approaches into drug development. Stuart is an inventor on several patents, authored 20 journal articles and presented at numerous global scientific and business conferences. He received a BA, High Honors at UCSC and a Ph.D. in Endocrinology at UC Berkeley, Cancer Research Lab (NCI Fellowship). He completed his post-doctoral work with Dr. JW Gray at UCSF & LBNL as a Distinguished Human Genome Postdoctoral Fellow (DOE).

Leslie is the Principal of Bottorff Advisors and focuses on leveraging her extensive experience in healthcare technology companies via board membership and/or consulting to mentor CEOs and teams, helping them to build new products and companies and accelerate growth. In her prior position, Leslie was Sr. Managing Director at GE Ventures, where she led the healthcare investing team. Her investment focus was primarily digital health, big data analytics, and IT/tech enabled devices and services.

Leslie is a strategic and operational leader with deep experience in coaching and mentoring entrepreneurs and start-up company teams that are impacting the healthcare industry with ground-breaking innovations. She has over 40 years’ experience in building companies as a venture capital investor, and as a key sales and marketing executive in both start-up and large medical companies. She has advised over 25 companies as a Board Member or Observer on strategic transformations, commercial accelerations, recruiting CEOs, successfully transitioning management teams through growth phases, supporting fund raising, facilitating exit strategies, and corporate governance compliance.

As a venture capital investor at both private institutional and large corporate venture firms, Leslie’s investment focus included digital health, healthcare IT/software, data analytics and medical technology. Her experience includes leading and syndicating equity rounds, facilitating relationships with corporate partners for strategic deals, and obtaining exits via IPO or M & A. She has worked with a diverse range of companies from seed to late commercial stage in multiple sub-sectors, business models, and clinical specialties. She is a frequent speaker at major industry conferences on new market opportunities created by applying new IT technologies such as AI and cloud connectivity to transform the delivery of healthcare.

Leslie is also a veteran operating executive in the medical device industry, serving in senior sales and marketing roles while leading companies through both product development and rapid commercial growth stages. She is an innovative leader who has built teams from scratch, successfully launched a wide array of novel medical devices, defined and implemented strategies, developed new products, created new markets, and pioneered adoption of new medical procedures and applications for both large multinational corporations and venture backed start-up companies.

Leslie received her MBA from Harvard Business School and BS in Interdisciplinary Engineering with concentration in biomedical and electrical engineering from Purdue University. She has served on advisory boards or as guest faculty at several universities, including Stanford, UC Berkeley, and Purdue University.

Dr. Simon is a rheumatologist and Principal at SDG, LLC. He has been the Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products (DAAODP) (2001-2003), within the Center for Drug Evaluation and Research (CDER), FDA. He has served on and has been the Acting Chair of the Arthritis Advisory Committee of the DAAODP (1993-2001). He has also served on the advisory committees for the Division of Over the Counter Drugs (1996), Center for Devices (1995), and for the Division of Hematologic and Gastroenterologic Drug Products (1996).

He has been a clinical Rheumatologist for 25 years. He is a fellow of the American College of Physicians (1991) and a Master of American College of Rheumatology (2019). He was at Harvard Medical School and the BIDMC as an Associate Professor of Medicine (1996-2001) and as an Associate Clinical Professor of Medicine (2001-2008). Dr. Simon has had extensive experience in drug development in the US, and has served on consulting advisory boards for many different companies. He was a National Institutes of Health (NIH) funded investigator for 12 years working at the “wet bench” at the MGH .

He has served for two terms on the Board of Directors of the American College of Rheumatology (ACR) (1991-1993, 1994-1997), served as the Chair of Education for the ACR and on the committee of the National Arthritis Foundation. He has served as the Scientific Abstract Selection Chair of the Annual Meeting of the ACR (2002). He has been awarded the 2003 Distinguished Service Award of the ACR and has been awarded the 2003 Scientific Leadership Award of the Lupus Research Institute. He served on the Steering Committee of IMPAACT, a group developing recommendations for the design and implementation of clinical trials investigating pain and now on the steering Committee of ACTTION, a public private partnership with FDA studying improved clinical trials designs and outcomes for both acute and chronic pain. He is on the Steering Committee and was Co-chair of the 2012, 2020, 2023 OMERACT (Outcome Measures in Rheumatology) Biannual Meeting. He served on the Steering Committee of the NIH Osteoarthritis Initiative (2001-2003). Dr. Simon has served as Chair of the biannual “Innovative Therapies in “Autoimmune Disease” conference sponsored by the ACR, FDA, NIH, and the Arthritis Foundation (2001-2005).

Lucy Lu has more than 25 years of biotech industry experience and has been a consultant to Inmedix since 2020. She most recently served as the President of North America Operations for Syncell, Inc., a biotech startup with an innovative spatial biology platform technology. From 2008 to 2014, Lucy served as SVP of Corporate and Business Development at Crescendo Bioscience. During her six years at Crescendo, she helped raise $90M in venture funding, supported the development and commercialization of a novel rheumatoid arthritis biomarker test, Vectra DA, until Crescendo’s acquisition by Myriad Genetics in 2014.

Prior to joining Crescendo, Lucy was Vice President of the US Chief Technology Office at Roche Diagnostics and was responsible for global technology scouting and assessment to support Roche Diagnostics portfolio growth. In her early career, Lucy worked on drug development at Genentech and BMS before switching to market novel life science tools at Applied Biosystems.

Lucy holds a BS degree in Botany from National Taiwan University, an MS degree in Plant Biology from University of Illinois and an MBA from St. Mary’s College.

Dr. Holman is the founding rheumatologist at Pacific Rheumatology Associates Inc PS, Director of Research at Pacific Rheumatology Research Inc., a former President of the Northwest Rheumatism Society (2005) and a Clinical Associate Professor of Medicine at the University of Washington.   He has 25 year clinical and 19 year rheumatology research career experience with 16 lead author published papers, 25 lead author published abstracts.   For Inmedix, he has designed, completed and published 15 clinical studies, including FDA negotiations, involving nearly 1500 patients.

With Tim Sciarrillo, Dr. Holman founded Inmedix, and after 3 prospective, clinical trials, eventually sold an international patent portfolio to Boehringer-Ingelheim for $10,000,000 in 2007.  In 2015, Dr. Holman converted Inmedix LLC into Inmedix Inc to bring next-generation heart rate variability (HRV) to clinicians on a reimbursed, scalable and actionable cloud platform.

Dr. Holman's research highlights include reporting and eventually licensing use of dopamine agonists as a treatment of fibromyalgia, exploring the impact of hypermobility syndromes, evaluating established and innovative autonomic nervous system (ANS) analysis with 5-min heart rate variability (HRV) in patients with rheumatoid arthritis and other autoimmune diseases, and broadening understanding of pain in patients with PC3 (positional cervical cord compression) using dynamic flexion-extension, cervical magnetic resonance imaging (dMRI). 

www.linkedin.com/in/AndrewJHolman

Prior to joining Inmedix, Steven was part of the executive management team of Light Sciences Oncology, a private venture-backed biotechnology company that raised over $250 Million to develop a combinational product (drug and device) for the treatment of cancer and other indications.  Over his 17 years at Light Sciences Oncology Steven held positions with escalating responsibility from design engineering, product development, non-clinical research, business development and licensing, market research, and corporate strategy and development.  He was intimately involved in the growth of Light Sciences from the startup phase through late stage clinical testing and eventual out-licensing of the technology.  Light Sciences investigated and researched its proprietary platform technology in 7 Phase 1 Studies, 5 Phase 2 Studies, and 2 Phase 3 Studies within 3 separate IND’s.  Steven holds a B.S. in Materials Science Engineering (Ceramic Engineering), M.S. in Bioengineering (Medical Engineering), and an M.B.A. from the University of Washington.

Larry Bock was the first Inmedix Board member and guided CEO Dr. Holman to develop Inmedix in its early stages.  Their relationship went back 40 years to being roommates at Bowdoin College.  Larry honed his exceptional intellect, drive, communication skills and business vision with an MBA from UCLA and worked in the very early days at Genentech.  Larry founded, co-founded or financed the early stage of forty companies from inception to an aggregate market capitalization of $70 Billion.  The companies he founded included Illumina, ARIAD, Pharmacopeia, Neurocrine, Calliper, NanoSys and many more.  Larry also founded the USA Science & Engineering Festival, the ‘Super Bowl of STEM.”

https://youtu.be/DI7_Ubi9BKQ

Inmedix is proud to support the USAS & EF and we created our oncology initiative, the LB Project, in his honor.  Our friend and mentor sadly passed away from pancreatic cancer in 2016.

Bernie Tobin is a 25-year veteran of the healthcare industry with his most recent role serving as President of Crescendo Bioscience, a wholly owned subsidiary of Myriad Genetics. Crescendo focused on using proteomics to deliver precision medicine to patients with autoimmune disorders.

Mr. Tobin oversaw 30%+ compounded annual growth rate (CAGR) in operating income achieved over 5 years via a series of strategic changes and operational execution across virtually all functional areas to include realignment of the senior leadership team, recruitment of new leaders, relocation of operations, changing market positioning, and launching multiple product enhancements.  His other notable achievements at Crescendo include:

●  Achieved guideline placement with the American College of Rheumatology, the first multi- biomarker test to accomplish this.

●  55% increase in physician adoption of their flagship product over 5 years.

Previously, Mr. Tobin held several senior level positions at Amgen including General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence. In addition, he led the global integration of a business development acquisition in over 100 countries. Prior to that, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co.  He received his B.S. degree in Public Service and Administration from Iowa State University and his M.B.A. from the Fuqua School of Business, Duke University.

https://www.linkedin.com/in/bernie-tobin-2952315/

Brianna McDonald has been an active leader and angel investor with Keiretsu Forum since its launch in Seattle in 2005 and supporting its growth to become the largest and most active group globally.  She has proven specifically adept at screening companies for angel investment, coaching companies on presentation and investor relations, sales strategy execution, relationship management, and leading due diligence teams. Brianna has established a reputation for achievement in all phases of the Keiretsu process: risk management, market anticipation and response, regional/national business development, organizational development, angel investing, and overall enterprise management.
 
She brings an impressive record of leadership in both the private and public arenas.  She has proven herself the consummate professional through her ability to build and develop diverse, productive and loyal teams through consensus building and mutual respect.  She has shared this focus on team building with members and clients so that whatever their role is in Keiretsu they feel valued and important. 
 
Brianna believes that business leaders should also be community leaders.  As such she sits on a variety of public and nonprofit boards, is a dedicated charity fundraiser, and a mentor to business and entrepreneurial educational programs including the University of Washington and Seattle University.  Brianna and her husband live in Seattle, Washington and with their three young children.

A world-renowned scientist and recipient of the National Medal of Science in 2011, Dr. Leroy Hood co-founded the Institute for Systems Biology (ISB) in 2000 and served as its first President from 2000-2017. In 2016, ISB affiliated with Providence St. Joseph Health (PSJH) and Dr. Hood became PSJH’s Senior Vice President and Chief Science Officer. He is also Chief Strategy Officer and Professor at ISB.

He is a member of the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine. Of the more than 6,000 scientists worldwide who belong to one or more of these academies, Dr. Hood is one of only 20 people elected to all three.

He received his MD from Johns Hopkins University School of Medicine and his PhD in biochemistry from Caltech. Dr. Hood was a faculty member at Caltech from 1967-1992, serving for 10 years as the Chair of Biology. During this period, he and his colleagues developed four sequencer and synthesizer instruments that paved the way for the Human Genome Project’s successful mapping and understanding of the human genome. He and his students also deciphered many of the complex mechanisms of antibody diversification. In 1992, Dr. Hood founded and chaired the Department of Molecular Biotechnology at the University of Washington, the first academic department devoted to cross-disciplinary biology.

Dr. Hood is currently carrying out studies in Alzheimer’s Disease, cancer, and wellness. He is pioneering a 1 million patient genome/phenome project for Providence St. Joseph Health and is bringing scientific (quantitative) wellness to the contemporary U.S. health care system.

Dr. Hood has played a role in founding 15 biotechnology companies including Amgen, Applied Biosystems, Arivale, and Nanostring. He has co-authored textbooks in biochemistry, immunology, molecular biology, genetics, and systems biology.

In addition to having received 18 honorary degrees from prestigious universities in the U.S. and abroad, Dr. Hood has published more than 850 peer-reviewed articles and currently holds 36 patents.

Dr. Hood is the recipient of numerous national and international awards, including the Lasker Award for Studies of Immune Diversity (1987), the Kyoto Prize in advanced technology (2002), the Heinz Award for pioneering work in Systems Biology (2006), the National Academy of Engineering Fritz J. and Delores H. Russ Prize for developing automated DNA sequencing (2011), and the National Academy of Science Award for Chemistry in Service to Society (2017).

Kevin J. Tracey is president and CEO and the Karches Family Distinguished Chair in Medical Research at the Feinstein Institutes for Medical Research; professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; and Executive Vice President, Research, at Northwell Health. A leader in the scientific fields of inflammation and bioelectronic medicine, his contributions include discovery and molecular mapping of neural circuits controlling immunity.

Dr. Tracey received his BS in chemistry, summa cum laude, Phi Beta Kappa, from Boston College in 1979, and his MD from Boston University in 1983. He trained in neurosurgery from 1983 to 1992 at the New York Hospital-Cornell University Medical Center and was a guest investigator at the Rockefeller University before moving in 1992 to the Feinstein Institutes. There he directs the Laboratory of Biomedical Science and was appointed president and CEO in 2005.

An inventor of more than 120 United States patents and author of more than 400 scientific publications, he cofounded the Global Sepsis Alliance, a non-profit organization supporting the efforts of more than 1 million sepsis caregivers in over 70 countries. Dr. Tracey is the author of Fatal Sequence (Dana Press) and delivers lectures nationally and internationally on inflammation, sepsis, the neuroscience of immunity, and bioelectronic medicine.

Ryan Sullivan works as an economist and serves as a Managing Director of Secretariat Advisors. He applies his expertise in economics, finance, and statistics to solve complex and challenging issues that organizations face in the competitive marketplace.

Dr. Sullivan has wide-ranging experience with the economics of intellectual property and technology. He develops and implements state-of-the-art predictive models that provide reliable, evidence-based insights into business outcomes. These predictive models are implemented across a spectrum of business challenges, including price optimization, promotional programs, business strategy, forecasting, and investing.

Dr. Sullivan earned his B.A., M.A., and Ph.D. in economics from the University of California, San Diego. He has published economic research in top-tier, peer-reviewed academic journals, as well as articles on the economics of intellectual assets. Dr. Sullivan served as an invited member of the Economics Leadership Council at the University of California, San Diego. And he served as the Treasurer and an officer on the Board of Trustees for the San Diego Zoo Wildlife Alliance.

Dr. Sullivan has provided professional economic services since 1992.